# 2020 EMERGING THERAPIES FOR PBC, NASH, ESLD AND HCC SEMINAR SERIES

## San Francisco, CA  March 7, 2020

### Conference Location
Embassy Suites - San Francisco Airport –
250 Gateway Blvd,
South San Francisco, CA
Phone: (650) 589-3400

### Parking at the Conference
Reduced self-parking rate has been arranged for program participants
Once you enter the self-parking area, bring the parking ticket to the Seminar Registration Desk

### Driving Directions
- **From San Francisco and Marin** – Take Highway 101 South, exit Grand Avenue, turn left on Airport Boulevard, turn left on Grand Avenue, turn left on Gateway Boulevard and the hotel is on the right hand side
- **From San Jose** from the East Bay on the San Mateo Bridge – Take Highway 101 North, exit Grand Avenue, turn left on Airport Boulevard, turn left on East Grand Avenue, turn left on Gateway Boulevard and the hotel is on the right hand side
- **From the East Bay** – Take the San Francisco Bay Bridge (I-80) take Highway 101-South and exit Grand Ave, turn left on Airport Blvd, turn left on East Grand Ave, turn left on Gateway Blvd and the hotel is on the right hand side.

### Seminar Agenda and Syllabus Information
Registration and breakfast begin at **7:30 a.m. in the Cypress Room.** Please check signage for any last minute room changes.

The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the App will be provided to participants in advance of the seminar. WiFi will be available without charge.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am</td>
<td><strong>Registration, Continental Breakfast &amp; View Exhibits</strong></td>
</tr>
<tr>
<td>8:00 am</td>
<td><strong>Opening Comments and Pre-Test</strong></td>
</tr>
<tr>
<td>8:20 am</td>
<td><strong>End Stage Liver Disease: Treatment, Managing Complications and Transplant</strong></td>
</tr>
<tr>
<td></td>
<td>• Staging, workup, and diagnosis of cirrhosis</td>
</tr>
<tr>
<td></td>
<td>• Medical care of the patient with end stage liver disease</td>
</tr>
<tr>
<td></td>
<td><strong>Liver Transplantation</strong></td>
</tr>
<tr>
<td></td>
<td>• Listing criteria, MELD scores, Exceptions and the transplant process</td>
</tr>
<tr>
<td></td>
<td><strong>Case Study 1 – Cirrhosis and Encephalopathy</strong></td>
</tr>
<tr>
<td>9:25 am</td>
<td><strong>Hepatocellular Carcinoma (HCC)</strong></td>
</tr>
<tr>
<td></td>
<td>• Screening diagnostic serum assays and imaging tests</td>
</tr>
<tr>
<td></td>
<td>• Diagnosis without histology</td>
</tr>
<tr>
<td></td>
<td>• Treatment and management options: Ablation, TACE and Surgery</td>
</tr>
<tr>
<td>10:00 am</td>
<td><strong>Break &amp; View Exhibits</strong></td>
</tr>
<tr>
<td>10:15 am</td>
<td><strong>Hepatocellular Carcinoma: New Systemic Treatment Options</strong></td>
</tr>
<tr>
<td></td>
<td>• Current FDA-Approved Therapies</td>
</tr>
<tr>
<td></td>
<td>• New chemotherapy regimens in development and testing</td>
</tr>
</tbody>
</table>
Immunotherapy as the new MoA for HCC

Case Study 2 – Diagnosis and Treatment of Hepatocellular Carcinoma

Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis
- Epidemiology of PSC and Ursodiol and Antibiotic Treatments
- Predicting outcomes and Improving Survival in PSC patients
- Causes and Markers of PBC
- Ursodeoxycholic Acid (UDCA) and Obeticholic Acid

Hepatology Update I – Viral Hepatitis
- The reemergence of Hepatitis A, Autoimmune Hepatitis and Transplanting HCV+ organs

Luncheon Presentation

Dessert and View Exhibits

Hepatology Update II Emerging Topics in Liver Disease
- Alcoholic Liver Disease, Liver disease and Pregnancy, Hepatorenal syndrome

NAFLD, LAL-D and NASH
- Epidemiology, Demographics and Diagnosis
- Treatment options for thrombocytopenia; including alternatives to platelet transfusion.
- Treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D) causing adult Fatty Liver Disease

Break & View Exhibits

NASH Treatments in Practice and in Development
- Current therapies for NASH
- Life style changes as a therapy
- Drugs in clinical development for NASH

Case Study 3 - NASH Diagnosis and Treatment

Post-test and Wrap-Up

Attendance Policies

Attendee Cancellation, Substitution, Refund
The course tuition is refundable, minus a $20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography
The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Guest Attendance
All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation
The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

CME Information

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.3 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-20-1150. The Kentucky Board of Nursing approval of an individual nursing education provide does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)™ organizations accredited by ACCME.
R. TODD FREDERICK, MD
Dr. Todd Frederick is a transplant Hepatologist with the San Francisco Center for Liver Disease at California Pacific Medical Center. He currently serves as Fellowship Director for Transplant Hepatology as well as the Director of Quality and Clinical Protocols for the Division. Dr. Frederick was appointed by San Francisco Mayor Gavin Newsom to serve on the Hepatitis C Task Force in 2009 where he assisted in drafting recommendations to the City for an approach to the HCV epidemic. Dr. Frederick is a member of several professional societies, including the American Gastroenterological Association, the American Association for the Study of Liver Diseases, and the European Association for the Study of the Liver.

DANIELLE BRANDMAN, MD, MAS
Dr. Danielle Brandman is a Hepatologist, who has expertise in treating patients with nonalcoholic fatty liver disease and patients needing liver transplants. She also treats conditions such as cirrhosis, primary biliary cholangitis, liver cancer, and primary sclerosing cholangitis. She serves as the hepatologist for the UCSF Polycystic Kidney Disease Center of Excellence. Dr. Brandman earned a medical degree at the New Jersey Medical School of Rutgers University, and completed an internal medicine internship and residency at UCSF. She also completed fellowships in gastroenterology and transplant hepatology. Brandman is an associate professor of medicine at UCSF. Dr. Brandman serves on the Medical Advisory Committee for the American Liver Foundation Northern California Chapter.

SARAH A. MILLER, NP, MPH
Sara A. Miller is a family nurse practitioner. She focuses on treating patients with end-stage liver disease (cirrhosis), patients undergoing liver transplant evaluation and specializes in non-alcoholic fatty liver disease. She also works with patients with liver cancer, hepatitis B, primary biliary cholangitis, primary sclerosing cholangitis and autoimmune hepatitis. NP Miller completed her Master in Nursing at UCSF Medical School of Nursing. She board certified by the American Association of Nurse Practitioners (AANP). She has been a member of the American Association for the Study of Liver Disease (AASLD) since 2016. She is a member of several special interest groups within AASLD including public health/health care delivery, non-alcoholic fatty liver disease, advance practice providers and the liver transplant groups. NP Miller is a co-investigator for several investigational studies reviewing novel medications for treatment of NASH. She is also a co-investigator on an observational studies looking at the natural history of NASH.